Risks and Benefits of Bisphosphonate Therapy in Osteopenia

Introduction to Osteopenia Treatment

The American College of Physicians recommends an individualized approach to starting bisphosphonate therapy in a healthy 65-year-old woman with osteopenia, weighing benefits against potential harms and costs based on baseline fracture risk 1

Low-quality evidence suggests that risedronate may reduce fracture risk in women with advanced osteopenia near the osteoporosis threshold, with a 73% relative risk reduction 2
Women with mild osteopenia will benefit substantially less than those with severe osteopenia 2

The incidence of osteonecrosis of the jaw is very rare at <1 case per 100,000 person-years with osteoporosis dosing 3, 4
The most consistent risk factor for osteonecrosis of the jaw is recent dental surgery or tooth extraction 3
Risk of osteonecrosis of the jaw increases with cumulative exposure beyond 5 years 3
The incidence of atypical femoral fractures ranges from 3.0 to 9.8 cases per 100,000 patient-years 3, 4
Risk of atypical femoral fractures begins to increase significantly after 5 years of treatment and escalates sharply beyond 8 years 3
Asian patients face up to 8 times higher risk of atypical femoral fractures 3
Despite this risk, an estimated 162 osteoporosis-related fractures are prevented for every one atypical femoral fracture associated with treatment 3

The American College of Physicians strongly recommends 5 years as the standard treatment duration 3
Evidence shows that increasing duration beyond 5 years probably reduces vertebral fractures but not other fractures, while increasing long-term harm risk 3
Factors favoring treatment include a T-score approaching -2.5, additional risk factors, and a high 10-year fracture risk 2, 5
Factors favoring observation include a T-score between -1.0 and -1.5, age 65 without additional risk factors, and no prior fractures 1, 2